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Background: HIV-uninfected infants born to HIV-infected mothers (HIV-exposed uninfected, HEU) have been
described to have immune alterations as compared to unexposed infants. This study sought to characterize T-cell
populations after birth in HEU infants and unexposed infants living in a semirural area in southern Mozambique.
Methods: Between August 2008 and June 2009 mother-infant pairs were enrolled at the Manhiça District Hospital
at delivery into a prospective observational analysis of immunological and health outcomes in HEU infants. Infants
were invited to return at one month of age for a clinical examination, HIV DNA-PCR, and immunophenotypic
analyses. The primary analysis sought to assess immunological differences between HEU and unexposed groups,
whereas the secondary analysis assessed the impact of maternal HIV RNA viral load in the HEU group. Infants who
had a positive HIV DNA-PCR test were not included in the analysis.
Results: At one month of age, the 74 HEU and the 56 unexposed infants had similar median levels of naïve,
memory and activated CD8 and CD4 T-cells. Infant naïve and activated CD8 T-cells were found to be associated
with maternal HIV-RNA load at delivery. HEU infants born to women with HIV-RNA loads above 5 log10 copies/mL had
lower median levels of naïve CD8 T-cells (p = 0.04), and higher median levels of memory CD8 T-cells, (p = 0.014).
Conclusions: This study suggests that exposure to elevated maternal HIV-RNA puts the infant at higher risk of having
early T-cell abnormalities. Improving prophylaxis of mother to child HIV programs such that more women have
undetectable viral load is crucial to decrease vertical transmission of HIV, but may also be important to reduce the
consequences of HIV virus exposure in HEU infants.
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Mother to child transmission (MTCT) of HIV occurs at
a rate of 15% to 40% in a breastfeeding population in the
absence of prevention measures [1]. However, pre-
vention of MTCT of HIV (pMTCT-HIV) through anti-
retroviral prophylaxis, cesarean deliveries and formula
feeding has successfully reduced MTCT to less than 1%
in resource-rich countries [2-4]. In Sub-Saharan African
countries, the last decade has witnessed a major rollout
of pMTCT-HIV programs, which has contributed to* Correspondence: dsuzanne@clinic.ub.es
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unless otherwise stated.dropping rates of vertical transmission of HIV. However,
with antenatal clinic HIV prevalence reaching 30% in
some countries [5,6], many infants are potentially ex-
posed to HIV, although remaining uninfected. These
HIV-exposed uninfected (HEU) infants may have im-
munological alterations which could lead to weakened
responses to infections and vaccines and vulnerability to
disease [7].
There is clear evidence that HEU infants present cyto-
penias including neutropenia as well as imbalances in
levels of total CD4 and CD8 T-cells [8-20]. There is also
increasing evidence that other immune abnormalities
may be present in HEU infants, albeit to differing de-
grees, such as, altered cytokine production or memory/
naïve T-cell skewing [10,11,13-15,21-24]. The durationl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have lower thymus output and increased immune activa-
tion as compared to unexposed infants [9,14,21]. How-
ever, reduced thymic size in HEU was not found to lead
to differences in T cell phenotypes or function between
HEU and unexposed infants at 15 months of age [25].
Some studies have suggested an important role of mater-
nal and infant antiretroviral exposure in triggering im-
munological alterations, but the impact remains unclear
[22,26]. HEU studies on lymphocytes and thymus output
have mainly been conducted in Europe, North America
and Brazil. The situation may be more complex in
Sub-Saharan Africa [19] where independently of HIV,
Africans have been shown to have lower levels of CD4,
naïve T-cells and increased levels of activated T-cells as
compared to Europeans [27-31]. In addition, environ-
mental and setting-specific factors affecting immuno-
logical indicators may vary widely in Sub-Saharan Africa.
For example, in areas of high malaria endemicity such as
Mozambique, cord blood lymphocytes from mothers in-
fected with malaria are often primed to parasite antigens
and exhibit higher level of activation [32,33].
The clinical consequences of immune alterations ob-
served in HEU infants are unknown. There has been an
observation that HEU infants may mount a weaker
immune response to BCG than infants born to HIV-
uninfected women [34,35]. Another consequence of im-
paired immunity could be that the severity, frequency and
mortality associated with infections is exacerbated in HEU
infants as compared to unexposed infants [36-39]; however
it is not clear whether this is due to specific immune alter-
ations [40-43] or to other mechanisms.
This study sought to characterize T-cell populations
after birth in HEU infants and unexposed infants living
in a semirural area in southern Mozambique where HIV
clade C is the predominant circulating virus.
Methods
Study population
This study was conducted from August 2008 to August
2010 at the Manhiça District Hospital in southern
Mozambique. The present study is integrated into a pro-
spective observational analysis of immunological and
health outcomes in infants born to HIV-infected mothers
which has been described elsewhere [20]. National guide-
lines for pMTCT-HIV during the study followed the 2006
World Health Organization (WHO) recommendation
[44]. At the time of the study, Highly Active Antiretroviral
Therapy (HAART) was indicated for women in WHO
disease stage 3 or 4 or CD4 < 250 counts/μl. For infants
whose mothers received a complete pMTCT-HIV was
based on a single dose of nevirapine (NVP) and daily zi-
dovudine (AZT) during 1 week post-delivery and for those
whose mothers did not receive a complete prophylaxis asingle dose of NVP and 4 weeks of daily AZT was recom-
mended. After the first month of the study, the pMTCT-
HIV national recommendation for children changed, and
4 weeks of daily AZT was recommended for all infants
born to HIV-infected mothers. pMTCT-HIV was consi-
dered complete for the mother if she had received all
treatments according to the guidelines, and for the new-
born if he/she had received one dose of nevirapine in the
first 72 hours after birth plus daily zidovudine for 4 weeks
after delivery [44]. Women were counselled to exclusively
breastfeed through 6 months. All HIV-infected mothers
and HIV-infected infants were referred to the day hospital
for clinical management according to national guidelines.
All participating mothers gave written informed con-
sent, and the study protocol was approved by the
Mozambican National Bioethics and the Hospital Clinic
of Barcelona Ethics Review Committees.
Study procedures
At enrolment HIV serology testing was performed in
the mothers using the Determine HIV-1/2 Rapid Test
(Abbott Laboratories, Abbott Park, IL) and positive
results were confirmed by the Uni-Gold Rapid Test
(Trinity Biotech Co., Wicklow, Ireland) according to
national guidelines. A 5 mL venous sample was drawn
from HIV-positive mothers for CD4 cell counts and viral
load determinations. Infants were invited to return at
one month of age for a clinical examination, HIV DNA-
PCR, and blood drawing. Infants who had a positive
HIV DNA-PCR test were not included in the analysis.
Due to the difficult blood extraction, several children did
not have enough blood for all the determinations. Only
the children with all the parameters available were in-
cluded in this analysis. The mother-infant pairs included:
1) HIV-infected mothers and their HEU infants and
2) HIV-uninfected mothers and their unexposed infants.
HIV serological and virological determinations
Infants were tested for HIV-1 using the Amplicor DNA-
PCR kit (Roche Diagnostics, Basel, Switzerland). HIV-
RNA quantification was performed from cryopreserved
plasma samples with the commercial Roche Amplicor
Monitor, version 1.5 (Roche Diagnostics, Basel, Switzerland).
The assay had a lower limit of detection of 400 HIV-1
RNA copies/mL. For the purpose of analyses, plasma
HIV-1 RNA concentrations below the limit of detection
were assigned the value of 200 copies/mL.
Immunophenotypic analysis
CD4 and CD8 counting was performed from fresh whole
blood after staining with labelled antibodies: CD4, CD3,
CD8, and CD45 in TruCount tubes (Becton Dickinson
Biosciences, California, USA). Samples were assessed by
flow cytometry on a FACS Calibur (Becton Dickinson).
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Dickinson Biosciences, California, USA).
To assess the percentage of activated CD4 and CD8 T
lymphocytes, cell staining was performed with CD3,
CD4 or CD8, CD38, and HLA-DR antibodies. Activated
T-cells were defined as those CD4 or CD8 T-cells ex-
pressing both CD38 and HLA-DR surface markers. The
percentage of naïve CD4 and CD8 was determined with
CD62L and CD45RA antibodies whereas the percentage
of memory CD4 and CD8 T-cells was evaluated by pan-
CD45RO antibody staining.
Statistical analysis and definitions
HEU infants were defined as those having a negative HIV-
DNA PCR test at 1 month of age. Parity was categorized
as primiparous if this was the first pregnancy and multip-
arous if the mother had had any previous pregnancy. Low
birth weight was defined as birth weight < 2500 grams.
Comparisons between groups for proportions were
assessed using the chi-square test or Fisher’s exact test
where appropriate. For the T-cell population studies, ana-
lyses were made on continuous variables. The Kruskal-
Wallis test was used to compare independent continuous
variables between groups. The Wilcoxon signed rank test
was used for analysis of paired data. The Spearman cor-
relation was used to assess correlations between non-
normally distributed continuous variables.
Statistical analysis was performed using STATA ver-
sion 12.0 (StataCorp, College Station, TX). The primary
analysis sought to assess immunological differences
between HEU and unexposed groups, whereas the sec-
ondary analysis assessed the impact of the maternal HIV
RNA viral load within the HEU group.Table 1 Demographic and clinical characteristics of mothers a
serostatus (n = 130)
HIV-infected
N = 74
Parity (n, %)
primigravidae 14 1
multigravidae 60 8
Age (yrs) [median (IQR)] 2
Low Birth weight, (n, %) 3 4
Birth weight (gr) [median (IQR)] 3
Sex, (n, %)
male 42 5
female 32 4
Maternal HIV RNA log10* (copies/mL) [median (IQR)] 3
Maternal CD4 counts (cells/μl) [median (IQR)] 6
IQR: interquartile range.
*Analysis is based on n = 63 infants with maternal HIV RNA measures available.Results
Study population
Between August 2008 and June 2009, 318 mothers, 158
HIV-infected women and 160 HIV-uninfected women
were enrolled at the Manhiça District Hospital [20]. Of
these, 110 HIV-infected and 75 HIV-uninfected women
came to the clinic at the infant’s one month visit and
were included in this study. Ten infants were de-
termined to be HIV-infected at 1 month of age and
excluded from the analysis. Of the remaining 175
mother-infant pairs, 130 infants had all immunological
measures at 1 month of age, (74 infants born to HIV-
infected mothers and 56 infants born to HIV-uninfected
mothers). The 45 mother-infant pairs lost to follow up
were comparable to the 130 used in this analysis in
terms of demographic characteristics (data not shown).
Demographic and clinical characteristics of mothers
and their infants at delivery were comparable between
HEU and unexposed groups (Table 1). The 130
mother-infant pairs included in this analysis were com-
parable to the overall study population in terms of par-
ity, age and birth weight and for HIV-infected women
in terms of CD4 counts and HIV RNA levels (data not
shown) [20]. At delivery the median maternal CD4
T-cell counts of HIV-infected mothers was 624 cells/μl
(IQR: 495–837) and 17% of the women had levels
below 350 CD4 cells/μl. Only 20.63% of the HIV-
infected women had undetectable HIV RNA at delivery
and median HIV RNA load was 3.91 log10 copies/mL
(IQR: 2.97-4.67). Eighty-two percent of HIV-infected
mothers received complete pMTCT-HIV. At one-
month of age, close to 90% of infants were receiving
exclusive breastfeeding.nd their infants at delivery according to maternal HIV
HIV-uninfected P
N = 56
8.92 11 19.64 0.917
1.08 45 80.36
5 (22–30) 23 (20–31) 0.335
.17 1 1.82 0.453
000 (2800–3300) 3100 (2900–3350) 0.253
6.76 23 41.07 0.077
3.24 33 58.03
.91 (2.97-4.67) NA
24 (495–837) NA
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unexposed infants at 1 month of age
To investigate the impact of maternal HIV infection on
the distribution of infant T-cells subsets, percent acti-
vated, naïve and memory CD4 and CD8 T-cell subsets
were assessed in HEU and UE infants.
At one month of age, the seventy-four HEU and the
fifty-six unexposed infants had similar median levels of
naïve, memory and activated CD8 and CD4 T-cells
(Figure 1).10
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Figure 1 Distribution of T-cell populations among HIV-exposed infect
for data from HEU (n = 74) and UE (n = 56) are indicated and plotted in sol
bubbles is proportional to number of observations. A, C, and E show naïve
naïve, memory and activated CD4 T-cell populations.The impact of maternal HIV viral load on levels of naïve
and memory CD8 T-cells
Within HEU infants, levels of naïve CD8 T-cells showed
a significant negative association with maternal HIV
RNA viral load (Spearman correlation: rho = −0.324,
p = 0.016) whereas levels of naïve CD4 T-cells were not
significantly associated with maternal HIV RNA (Figure 2).
Memory CD8 T-cells and activated CD8 T-cells were
positively associated with maternal HIV RNA viral load
(memory: Spearman rho = 0.293 p = 0.031 and activated:10
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Figure 2 Correlation between maternal HIV RNA viral load at
delivery and infant level of naïve CD8 T cells (A) and naïve CD4
T cells (B) at one month of age. Spearman correlation coefficient
Rho and its corresponding p-value is indicated for each graph.
Table 2 Levels of T-cell populations in HIV exposed
uninfected infants at 1 month of age according to
maternal HIV RNA viral load at delivery
Cell
population
HIV RNA ≥ 5 log10
(n = 6)
[median (IQR)]
HIV RNA < 5 log10
(n = 57)
[median (IQR)]
p-value*
CD8 T-cells
counts (cells/μl) 1585 (1080–1702) 1112 (71–1447) 0.14
activated (%) 25.8 (11.2-40.3) 8.8 (3.3-18.3) 0.09
naive (%) 54.3 (42.8-67.8) 79.8 (67.6-88.2) 0.04
memory (%) 54.6 (30.5-75.8) 21.9 (14.3-40.3) 0.014
CD4 T-cells
counts (cells/μl) 2594 (2174–3185) 2291 (1955–3028) 0.337
activated (%) 5.3 (4.0-7.8) 3.5 (2.1-6.5) 0.557
naive (%) 70.1 (60.4-74.8) 70.3 (60.6-78.9) 0.79
memory (%) 19.8 (15.4-21.7) 23.9 (13.2-45.8) 0.574
Analysis is based on n = 63 infants with maternal HIV RNA measures available.
*P-value from kruskal-wallis test.
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and memory CD4 T-cells were not significantly associated
with maternal HIV RNA viral load (p = 0.180, p = 0.733
respectively).
When HEU infants were categorized according to
their mothers HIV RNA at delivery, HEU infants born
to women with HIV viral load above 5 log10 copies/mL
had significantly lower levels of naïve CD8 T-cells and
higher levels of memory CD8 T-cells at 1 month of age
as compared to infants born to women with HIV RNA
level below 5 log10 copies/mL (Table 2). Maternal HIV
RNA above 5 log10 copies/mL was also associated with
increased levels of activated CD8 T-cells although this
did not reach significance. There were no associations
between maternal HIV RNA loads and levels of infant
naïve, activated or memory CD4 T-cells (Table 2). Theinfants born to women with high HIV RNA levels
remained HIV-uninfected at subsequent visits although
two were lost to follow up at the 12 month visit within
the prospective observational study.
Higher maternal CD4 counts at delivery were signifi-
cantly associated with higher level of infant naive CD4
T-cells (spearman correlation: rho = 0.365 p = 0.0018)
but not with naïve CD8 T-cells (spearman correlation:
rho = 0.007 p = 0.95) nor with memory CD4 or CD8
T-cells (p = 0.104 and p = 0.811 respectively).
Discussion
In this study, at one month of age, HEU and unexposed
infants had comparable median percentages of naïve,
memory and activated CD4 T-cells and CD8 T-cells.
However, within the HEU infant group, HEU born to
women with high maternal HIV RNA level at delivery
showed skewed naïve and activated CD8 T-cell popula-
tions at one month of age as compared to HEU infants
born to women with lower viral load. In addition, mater-
nal CD4 counts at delivery were positively associated
with levels of infant naïve CD4 T-cells.
A naïve immune system with little previous antigen
stimulation is expected to have high levels of naïve
T-cells and low activation. With age, the levels of naïve
cells decrease and memory cells increase reflecting
antigen exposure [45,46]. HIV-infected infants show an
activated phenotype whereby they display a decrease in
naïve CD4 and/or CD8 T-cells and an increase in
activated and memory T-cells [47]. Some studies have
suggested that HEU infants also have naïve/memory
T-cell skewing, albeit to a lesser extent, whereas other
studies have not observed this skewing in HEU
[11,13-15,19]. In the current study, differences in naïve/
de Deus et al. BMC Infectious Diseases  (2015) 15:37 Page 6 of 8memory T-cell skewing were not observed at one month
of age between HEU and UE. However, significantly
lower median %CD4 T-cells and higher %CD8 T-cells
were observed in these HEU as compared to UE [20].
The inconsistency in the literature regarding naïve/
memory T-cell skewing in HEU infants leads to specula-
tion as to the impact of factors such as time point of
measurement, comparability of birth outcomes between
HEU and UE infants, overall disease burden and mater-
nal viral load. Studies of thymic naïve T-cell output in
HEU infants by Nielsen et al., [14] found birth outcomes
such as gestational age, birth weight and mode of deliv-
ery to impact observed infant naïve T cell levels. This
could lead to confounding when assessing lymphocyte
subset differences between HEU and UE which have very
different birth outcomes. Additionally, time points for as-
sessment of lymphocyte subsets have ranged from birth to
adolescence, thus contributing to non-comparability of re-
sults. In our cohort, the birth weight, mode of delivery
and feeding was not significantly different between HEU
and unexposed infants. Since those infants requiring ur-
gent care at birth were not included in our study, the ab-
sence of naïve/memory lymphocyte skewing in HEU at
one month of age could be due to exclusion of those in-
fants with poor birth outcomes. Alternatively, Manhiça is
an endemic region of P. falciparum malaria and thus
heightened malaria-induced immune activation in new-
borns could have masked differences due to HIV ex-
posure. Our results showing correlation between maternal
HIV viral load and infant CD8 T cell skewing suggest that
only a sub population of HEU show T-cell skewing.
This study is one of the first to our knowledge to de-
scribe a relationship between maternal HIV RNA level
and naïve/memory skewing in CD8 T-cell populations in
HEU infants. This complements a recent study from
Canada which showed that high maternal viral load was
associated with higher levels of CD19+ B-cells in HEU
infants [48]. Both studies point to a dose-dependent as-
sociation of maternal HIV RNA level with lymphocyte
subset skewing. In most cohorts studied in resource-rich
countries, HIV viral load is undetectable or low due to
effective pMTCT-HIV. In the current study, despite the
existence of a pMTCT-HIV program, nearly 80% of
women had detectable viral load at delivery. Among the
HEU infants, linear associations were observed between
levels of maternal HIV RNA viral load at delivery and
naïve, pan-memory and activated CD8 T-cells. Maternal
HIV viral load greater than 5 log10 copies/mL was asso-
ciated with a significantly lower percentage of naïve CD8
T-cells and a higher percentage of memory CD8 T-cells
as compared to HEU infants born to mothers with
maternal HIV RNA below 5 log10 copies/mL. In utero
infant exposure to maternal HIV particles and/or pro-
teins could lead to lymphocyte subset skewing but mayrequire a certain threshold or duration of maternal HIV
exposure to be observed. The existence of such a thresh-
old may help to explain inconsistent results in HEU
immune abnormalities across studies. Additionally, in
breastfeeding populations, the infant is potentially con-
tinuously exposed to HIV through breastmilk which
would be higher in those women with higher plasma
HIV RNA levels.
The main study limitations are the small sample size,
particularly in the high maternal HIV RNA group, and
the lack of evaluation of the duration of the T-cell
skewing. Further studies including monitoring breast
milk viral load exposure will be necessary. The analysis
of memory T-cells was performed using the CD45RO
marker, which is a non-specific marker of mature pheno-
type T-cells and does not distinguish between central
and effector memory. The use of CD45RO may have
underestimated levels of memory cells by excluding stem
cell memory cells which are CD45RO [49] but this
would have affected both HEU and UE groups. Other
more specific markers that require greater than 4-color
flow cytometry could not be assessed in Manhiça.
Conclusions
In conclusion, HEU infants born to women with high ma-
ternal HIV RNA level at delivery had skewed naïve and ac-
tivated CD8 T-cell populations at one month of age.
Improving pMTCT-HIV programs such that more women
have undetectable viral load is crucial to decrease vertical
transmission of HIV, but may also be important to reduce
the consequences of HIV virus exposure in HEU infants.
The current recommendation of HAART for all HIV-
infected pregnant women (the B+ option) is promising
and will serve to reduce infant HIV exposure in Sub-
Saharan Africa [50]. However, there will be a lag time until
infant HIV exposure is eliminated in the region, thus elu-
cidation of the clinical relevance of infant’s exposure to
maternal HIV [20,51-53] and its impact on altered T-cell
populations should remain a priority.
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